Notably, anti-tumorigenic activity was significantly enhanced when sorafenib or regorafenib treatment was combined with STK25 knockdown, and the silencing of STK25 had a similar impact in sorafenib-naïve and sorafenib-resistant hepatoma cells. Here, STK25 is linked to hepatocellular carcinoma.